Ionis Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ionis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#286 of 15,742 sponsors by registered trial count).
Ionis Pharmaceuticals: 76 sponsored US clinical trials, 9 recruiting.
Ionis Pharmaceuticals sponsors 76 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 52 completed. 21 of these trials are in Phase 3-4 (later-stage) and 48 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), with 3 trials.
Top-decile sponsor footprint
Ionis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#286 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
52 of 55 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
76 total, page 2 of 2
A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients
NCT02476019
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
NCT02300233
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
NCT02211209
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
NCT02312011
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
NCT02175004
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes
NCT01885260
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
NCT01737398
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
NCT01647308
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers
NCT01563302
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
NCT01529424
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
NCT01234038
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
NCT01234025
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
NCT01041222
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
NCT00365781
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
NCT00330200
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
NCT00062816
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.
NCT00063830
ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
NCT00063414
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
NCT00048321
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
NCT00035945
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
NCT00048113
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
NCT00017407
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
NCT00002356
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
NCT00002187
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
NCT00002355
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
NCT00002156
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 28 |
| Phase 3 | 21 |
Therapeutic Areas
What is open in the Ionis Pharmaceuticals pipeline
9 recruiting of 76 indexed (12% open); 52 completed (68%).
Phase mix: 21 late (III/IV) vs 48 early (I/II) (early-phase heavy).
Top condition: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ionis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 76 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Ionis Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 76 trials (± recruiting share)
- MetroHealth Medical Center · 76 trials · 13% recruiting
- Texas Tech University Health Sciences Center · 76 trials · 13% recruiting
- University of New Mexi · 76 trials · 30% recruiting
- University of Hawaii · 77 trials · 17% recruiting
Sponsors near 12% open enrollment (± trial volume)
- United States Army Research Institute of Environmental Medicine · 12% recruiting · 59 trials
- Fred Hutchinson Cancer Center · 12% recruiting · 483 trials
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
Related
What to do with this Ionis Pharmaceuticals page
76 registered trials is a research-attention snapshot, not an endorsement of Ionis Pharmaceuticals or any single study.
- 9 of Ionis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) is the condition Ionis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ionis Pharmaceuticals pipeline card: 76 registered trials from official public datasets.Report a data error.